The stock was sold at an average price of $17.81, for a total value of $209,997. The company has a one-year low of $1,309 and a one-year high of $1,847.
The company’s fourth quarter revenue was up 2 percent to $1.2 billion. The trading profit was up 7 percent to $325 million and the global advanced wound management business line was down 2 percent. Also, the full year, revenue was up 2 percent to $4.6 billion.
More articles on devices:
27 spine devices receive FDA 510(k) clearance in January
MiMedx withdraws complaint against Organogenesis
NuVasive COO sells 15k shares — 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
